Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06383572 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
A Phase 1 study of Myeloid Malignancies and Lymphodepleting Chemotherapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06383572 is a Phase 1 study of Myeloid Malignancies and Lymphodepleting Chemotherapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 44 participants, roughly in line with the 43-participant average among 5 other Myeloid Malignancies trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06383572, a Phase 1 study of Myeloid Malignancies and Lymphodepleting Chemotherapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Decitabine
- DRUG Fludarabine phosphate
- DRUG Dexamethasone
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2029-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06383572
The ClinicalTrials.gov registry entry for NCT06383572 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 43-participant average among 5 other Myeloid Malignancies trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myeloid Malignancies appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT06383572 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06383572 about?
NCT06383572 is a clinical study titled "Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies". To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
What is the current status of trial NCT06383572?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2024-06-26. Estimated completion is 2029-04-01.
What conditions does trial NCT06383572 study?
This clinical trial studies the following conditions: Myeloid Malignancies, Lymphodepleting Chemotherapy.
What interventions are being tested in trial NCT06383572?
The interventions under investigation include: Cyclophosphamide (DRUG), Decitabine (DRUG), Fludarabine phosphate (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT06383572?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06383572 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
RECRUITING · Phase 1
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
RECRUITING · Phase 2
-
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
COMPLETED · Phase 2
-
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.